Research programme: Duchenne muscular dystrophy therapeutics - Idera Pharmaceuticals/Parent Project Muscular Dystrophy
Latest Information Update: 11 Nov 2014
At a glance
- Originator Idera Pharmaceuticals
- Class Nucleic acids
- Mechanism of Action Toll-like receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 07 Nov 2014 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)